Literature DB >> 22187965

The causal exposure model of vascular disease.

Allan D Sniderman1, Patrick R Lawler, Ken Williams, George Thanassoulis, Jacqueline de Graaf, Curt D Furberg.   

Abstract

Primary prevention of cardiovascular disease is governed at present by the risk factor model for cardiovascular events, a model which is widely accepted by physicians and professional associations, but which has important limitations: most critically, that effective treatment to reduce arterial damage is often delayed until the age at which cardiovascular events become common. This delay means that many of the early victims of vascular disease will not be identified in time. This delay also allows atherosclerosis to develop and progress unchecked within the arterial tree with the result that the absolute effectiveness of preventive therapy is limited by the time it is eventually initiated. The causal exposure model of vascular disease is an alternative to the risk factor model for cardiovascular events. Whereas the risk factor model aims to identify and treat those at markedly increased risk of vascular events within the next decade, the causal exposure model of vascular disease aims to prevent events by treating the causes of the disease when they are identified. In the risk factor model, age is an independent non-modifiable risk factor and the predictive power of age far outweighs that of the other risk factors. In the causal exposure model, age is the duration of time the arterial wall is exposed to the causes of atherosclerosis: apoB (apolipoprotein B) lipoproteins, hypertension, diabetes and smoking. Preventing the development of advanced atherosclerotic lesions by treating the causes of vascular disease is the simplest, surest and most effective way to prevent clinical events.

Entities:  

Mesh:

Year:  2012        PMID: 22187965      PMCID: PMC3244267          DOI: 10.1042/CS20110449

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  22 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  The effect of including C-reactive protein in cardiovascular risk prediction models for women.

Authors:  Nancy R Cook; Julie E Buring; Paul M Ridker
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

3.  Relative importance of borderline and elevated levels of coronary heart disease risk factors.

Authors:  Ramachandran S Vasan; Lisa M Sullivan; Peter W F Wilson; Christopher T Sempos; Johan Sundström; William B Kannel; Daniel Levy; Ralph B D'Agostino
Journal:  Ann Intern Med       Date:  2005-03-15       Impact factor: 25.391

4.  Multiple biomarkers for the prediction of first major cardiovascular events and death.

Authors:  Thomas J Wang; Philimon Gona; Martin G Larson; Geoffrey H Tofler; Daniel Levy; Christopher Newton-Cheh; Paul F Jacques; Nader Rifai; Jacob Selhub; Sander J Robins; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

5.  The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke.

Authors:  M R Law; N J Wald; J K Morris
Journal:  J Med Screen       Date:  2004       Impact factor: 2.136

6.  Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study.

Authors:  M R Law; N J Wald; T Wu; A Hackshaw; A Bailey
Journal:  BMJ       Date:  1994-02-05

7.  Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.

Authors:  Donald M Lloyd-Jones; Eric P Leip; Martin G Larson; Ralph B D'Agostino; Alexa Beiser; Peter W F Wilson; Philip A Wolf; Daniel Levy
Journal:  Circulation       Date:  2006-02-06       Impact factor: 29.690

8.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28

9.  Framingham risk score and prediction of lifetime risk for coronary heart disease.

Authors:  Donald M Lloyd-Jones; Peter W F Wilson; Martin G Larson; Alexa Beiser; Eric P Leip; Ralph B D'Agostino; Daniel Levy
Journal:  Am J Cardiol       Date:  2004-07-01       Impact factor: 2.778

10.  Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease.

Authors:  Allan D Sniderman; Ingar Holme; Are Aastveit; Curt Furberg; Goran Walldius; Ingmar Jungner
Journal:  Am J Cardiol       Date:  2007-05-30       Impact factor: 2.778

View more
  7 in total

1.  Low-density lipoprotein cholesterol versus particle number in middle school children.

Authors:  Michele Mietus-Snyder; Kimberly L Drews; James D Otvos; Steven M Willi; Gary D Foster; Russell Jago; John B Buse
Journal:  J Pediatr       Date:  2013-02-14       Impact factor: 4.406

2.  Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women.

Authors:  Patrick R Lawler; Akintunde O Akinkuolie; Paul M Ridker; Allan D Sniderman; Julie E Buring; Robert J Glynn; Daniel I Chasman; Samia Mora
Journal:  Clin Chem       Date:  2017-02-07       Impact factor: 8.327

3.  A study of prognostic factors in Chinese patients with diabetic foot ulcers.

Authors:  Aiping Wang; Xinjuan Sun; Wei Wang; Kechun Jiang
Journal:  Diabet Foot Ankle       Date:  2014-03-11

4.  A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor.

Authors:  Alastair G Kerr; Lawrence C S Tam; Ashley B Hale; Milena Cioroch; Gillian Douglas; Sarina Agkatsev; Olivia Hibbitt; Joseph Mason; James Holt-Martyn; Carole J R Bataille; Graham M Wynne; Keith M Channon; Angela J Russell; Richard Wade-Martins
Journal:  J Pharmacol Exp Ther       Date:  2017-03-30       Impact factor: 4.030

Review 5.  There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.

Authors:  Michael E Makover; Michael D Shapiro; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2022-08-06

Review 6.  Medicine 2032: The future of cardiovascular disease prevention with machine learning and digital health technology.

Authors:  Aamir Javaid; Fawzi Zghyer; Chang Kim; Erin M Spaulding; Nino Isakadze; Jie Ding; Daniel Kargillis; Yumin Gao; Faisal Rahman; Donald E Brown; Suchi Saria; Seth S Martin; Christopher M Kramer; Roger S Blumenthal; Francoise A Marvel
Journal:  Am J Prev Cardiol       Date:  2022-08-29

7.  Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Jing Cao; Sarah O Nomura; Brian T Steffen; Weihua Guan; Alan T Remaley; Amy B Karger; Pamela Ouyang; Erin D Michos; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2019-11-29       Impact factor: 4.766

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.